Catherine Jia
About
Catherine Jia is a scholar working on Epidemiology, Hematology and Genetics.
According to data from OpenAlex, Catherine Jia has authored 25 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 8 papers in Hematology and 6 papers in Genetics. Recurrent topics in Catherine Jia's work include Liver Disease Diagnosis and Treatment (10 papers), Acute Lymphoblastic Leukemia research (6 papers) and CAR-T cell therapy research (5 papers). Catherine Jia is often cited by papers focused on Liver Disease Diagnosis and Treatment (10 papers), Acute Lymphoblastic Leukemia research (6 papers) and CAR-T cell therapy research (5 papers). Catherine Jia collaborates with scholars based in United States, United Kingdom and Germany. Catherine Jia's co-authors include Robert P. Myers, Andrew J. Muir, Zachary Goodman, Nezam H. Afdhal, B. Mccolgan, John G. McHutchison, Mitchell L. Shiffman, G. Mani Subramanian, Stephen H. Caldwell and Stephen A. Harrison and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.
In The Last Decade
Catherine Jia
24 papers receiving 717 citations
Hit Papers
Peers
Catherine Jia
Nicholas Nissen United States
John Frye United States
Ömer Yerci Türkiye
Annette Jappe Switzerland
Ji-Na Zheng China
Stéphane Zalinski France
Akihisa Nagatsu Japan
Ayşe Ocak Duran Türkiye
Atsushi Takeshita Japan
Donald F. Chute United States
Citations per year, relative to Catherine Jia Catherine Jia (= 1×)
peers
Nicholas Nissen
Countries citing papers authored by Catherine Jia
Since
Specialization
Citations
This map shows the geographic impact of Catherine Jia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Jia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Jia more than expected).
Fields of papers citing papers by Catherine Jia
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Catherine Jia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Jia. The network helps show where Catherine Jia may publish in the future.
Co-authorship network of co-authors of Catherine Jia
This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Jia. A scholar is included among the top collaborators of Catherine Jia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Jia. Catherine Jia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Jun, Dora Ding, Xiaorong Shao, et al.. (2025). Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis. Diabetes Obesity and Metabolism. 27(8). 4148–4156.
2.
Loomba, Rohit, Naim Alkhouri, Mazen Noureddin, et al.. (2024). TOP-264 Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). Journal of Hepatology. 80. S505–S505.
3.
Casale, Francesco Paolo, Rohit Loomba, Arun J. Sanyal, et al.. (2022). Machine learning encoding of liver biopsy images enables prediction of molecular measurements in a NASH F3/F4 fibrosis clinical cohort. Journal of Hepatology. 77. S409–S409.
4.
Sanyal, Arun J., Quentin M. Anstee, Michael Trauner, et al.. (2021). Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 75(5). 1235–1246.
5.
Glass, Benjamin, Hunter Elliott, Ling Han, et al.. (2020). Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis. Journal of Hepatology. 73. S402–S402.
6.
Lawitz, Eric, Edward Gane, Peter Ruane, et al.. (2019). SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 70(1). e794–e794.
7.
Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, et al.. (2019). The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 70(6). 1913–1927.
8.
Stein, Anthony S., Gary J. Schiller, Ramsis Benjamin, et al.. (2018). Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Annals of Hematology. 98(1). 159–167.
9.
Lawitz, Eric, Robert Herring, Ziad Younes, et al.. (2018). Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH. Gastroenterology. 154(6). S–1166.
10.
Harrison, Stephen A., Mazen Noureddin, Robert Herring, et al.. (2018). Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH. Gastroenterology. 154(6). S–1166.
11.
Muir, Andrew J., Cynthia Levy, Harry L.A. Janssen, et al.. (2018). Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology. 69(2). 684–698.
12.
Sanyal, Arun J., Stephen A. Harrison, Vlad Ratziu, et al.. (2017). Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis. Gastroenterology. 152(5). S1055–S1055.
13.
Kantarjian, Hagop M., Anthony S. Stein, Ralf C. Bargou, et al.. (2016). Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 122(14). 2178–2185.
14.
Zeng, Donglin, Fei Gao, Kuolung Hu, Catherine Jia, & Joseph G. Ibrahim. (2015). Hypothesis testing for two‐stage designs with over or under enrollment. Statistics in Medicine. 34(16). 2417–2426.
15.
Kantarjian, Hagop M., Anthony S. Stein, Ralf C. Bargou, et al.. (2015). Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies.. Journal of Clinical Oncology. 33(15_suppl). 7043–7043.
16.
Goekbuget, Nicola, Hagop M. Kantarjian, Monika Brüggemann, et al.. (2014). An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE® Antibody Construct Blinatumomab. Blood. 124(21). 3704–3704.
17.
Sekeres, Mikkael A., Aristoteles Giagounidis, Hagop M. Kantarjian, et al.. (2014). Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes. British Journal of Haematology. 167(3). 337–345.
18.
Zeng, Donglin, Joseph G. Ibrahim, Ming‐Hui Chen, Kuolung Hu, & Catherine Jia. (2014). Multivariate Recurrent Events in the Presence of Multivariate Informative Censoring with Applications to Bleeding and Transfusion Events in Myelodysplastic Syndrome. Journal of Biopharmaceutical Statistics. 24(2). 429–442.
19.
Stein, Anthony S., Max S. Topp, Nicola Goekbuget, et al.. (2014). Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood. 124(21). 965–965.
20.
Stasi, Roberto, Adrian C. Newland, Bertrand Godeau, et al.. (2013). An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim. Blood. 122(21). 1074–1074.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nicholas Nissen Breakdown of academic impact, for papers by John Frye Breakdown of academic impact, for papers by Ömer Yerci Breakdown of academic impact, for papers by Annette Jappe Breakdown of academic impact, for papers by Ji-Na Zheng Breakdown of academic impact, for papers by Stéphane Zalinski Breakdown of academic impact, for papers by Akihisa Nagatsu Breakdown of academic impact, for papers by Ayşe Ocak Duran Breakdown of academic impact, for papers by Atsushi Takeshita Breakdown of academic impact, for papers by Donald F. Chute